GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Dahabreh, IJ en
dc.contributor.author Giannouli, S en
dc.contributor.author Gota, V en
dc.contributor.author Voulgarelis, M en
dc.date.accessioned 2014-03-01T11:46:26Z
dc.date.available 2014-03-01T11:46:26Z
dc.date.issued 2010 en
dc.identifier.issn 0020-7136 en
dc.identifier.uri https://dspace.lib.ntua.gr/xmlui/handle/123456789/37906
dc.subject glutathione-S-transferace en
dc.subject GSTT1 en
dc.subject GSTM1 en
dc.subject myelodysplastic syndrome en
dc.subject meta-analysis en
dc.subject.classification Oncology en
dc.subject.other ACUTE MYELOID-LEUKEMIA en
dc.subject.other GENETIC POLYMORPHISMS en
dc.subject.other CLINICAL-TRIALS en
dc.subject.other LUNG-CANCER en
dc.subject.other BENZENE en
dc.subject.other EXPOSURE en
dc.subject.other GENOTYPE en
dc.subject.other DEFECT en
dc.title GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis en
heal.type other en
heal.language English en
heal.publicationDate 2010 en
heal.abstract Glutathione-S-transferace polymorphisms may make hematopoietic lineage cells susceptible to genotoxicity following exposure to heavy metals or benzene. We conducted a systematic review and meta-analysis to define the effect of GSTM1 and GSTT1 null polymorphisms on MDS risk. We searched the PubMed and SCOPUS databases to identify peer-reviewed published case-control studies investigating the association between GSTT1 and/or GSTM1 null genotypes and development of MDS. Between-study heterogeneity was assessed using Cochran's Q statistic and the I-2 statistic. Odds ratios from individual studies were pooled using fixed and random effects models. Thirteen studies were considered eligible for the GSTT1 meta-analysis (1471 cases, 1907 controls) and 10 were considered eligible for the GSTM1 meta-analysis (1161 cases, 1668 controls). For the GSTT1 polymorphism, there was moderate between study heterogeneity (p(Q) = 0.01; I-2 = 52.3%) and the null genotype was significantly associated with increased risk of MDS development, random effects OR = 1.43 (95% CI, 1.09-1.89); p = 0.01. For the GSTM1 polymorphisms there was moderate between-study heterogeneity (p = 0.07; I-2 = 43.1%) and the random effects OR = 1.02 (95% CI, 0.82-1.28) was non-significant (p = 0.85). The GSTT1 null genotype is a significant risk factor for MDS development. Gene-environment interactions need to be further explored. en
heal.publisher JOHN WILEY & SONS INC en
dc.identifier.isi ISI:000274940200018 en
dc.identifier.volume 126 en
dc.identifier.issue 7 en
dc.identifier.spage 1716 en
dc.identifier.epage 1723 en

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record